The Value of Prognostic Nutritional Index in Predicting Outcomes and Guiding Treatments for Nasopharyngeal Carcinoma Patients Treated by Intensity Modulated Radiation Therapy

J. Miao,W. Xiao,L. Wang,F. Han,H. Wu,X. Deng,X. Guo,C. Zhao

DOI: https://doi.org/10.1016/j.ijrobp.2016.06.541

2016-01-01

Abstract:The purpose of this study was to investigate the significance of the prognostic nutritional index (PNI) in predicting the prognosis and guiding the treatment choices for nasopharyngeal carcinoma (NPC) patients treated by intensity-modulated radiotherapy (IMRT). Five hundred thirty-nine patients with newly diagnosis stage I-IV NPC who received radical IMRT with or without chemotherapy were retrospectively analyzed. The PNI was calculated as 10 × serum albumin (g/dl) + 0.005 × total lymphocyte count (per mm3). All patients were split randomly into a training set (n = 239) and a testing set (n = 300) for analysis. The receiver operating characteristic (ROC) curves were calculated to identify the cut-off value of PNI and tested its prognostic validity. Survival curves were calculated by the Kaplan-Meier method and differences were compared with a log-rank test. Univariate and multivariate analysis were applied to identify the prognostic factors. Of the 539 patients, 63.8% patients received concurrent chemoradiotherapy (CCRT) with or without neoadjuvant/adjuvant chemotherapy. The median follow-up time was 101.3 months. The five-year loco-regional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS) of the whole cohort was 90.7%, 85.8%, 85.3%, and 83.1%, respectively. The cut-off value of PNI was 52.0 in the training set, which was significant in predicting DMFS, DSS, and OS in testing set and all patients (all P < 0.05). Multivariate analysis showed PNI was an independent prognostic factor on DMFS (P = 0.004), DSS (P < 0.001), and OS (P < 0.001) in the whole cohort. In order to explore the role of CCRT in the different PNI subclassifications of patients with stage II-IV, 220 patients who received CCRT alone were analyzed. In these 220 patients, 62 patients were in PNI ≤52.0, and 158 patients were in PNI >52.0. The 5-year DMFS, DSS, OS in patients with PNI ≤52.0 were significant worse than those with PNI >52.0 (76.0% vs. 86.4%, P = 0.039; 71.8% vs. 87.8%, P = 0.008; 67.7% vs. 84.8%, P = 0.008). Our results suggest that PNI is a reliable independent prognostic factor in NPC patients treated with IMRT. For locoregionally intermediate and advanced NPC patients with PNI≤52.0, CCRT alone could not achieve satisfactory treatment outcome, and further studies on treatment optimization are needed.